Business Context and Reporting Period
This Form 8-K, filed on May 14, 2025, by Acuren Corporation (the "Registrant"), announces the entry into a definitive Merger Agreement with NV5 Global, Inc. ("NV5"). The transaction involves a two-step merger where NV5 will become a wholly-owned subsidiary of Acuren. The filing details the terms of the combination, governance changes, financing arrangements, and conditions precedent to closing.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or margin data for either company. The primary financial metrics relate to the transaction structure and financing:
- Merger Consideration: NV5 shareholders will receive a combination of Acuren common stock and cash.
- Cash Component: $10.00 per share of NV5 common stock.
- Stock Component: Determined by an Exchange Ratio based on Acuren's 10-day volume-weighted average price (VWAP) prior to closing.
- If Acuren Closing VWAP is $\ge$ $11.65: Exchange Ratio is 1.1157 shares.
- If Acuren Closing VWAP is $\le$ $9.53: Exchange Ratio is 1.3636 shares.
- Financing: Acuren has secured a debt commitment for $875.0 million to fund the transaction, consisting of an $850.0 million senior secured incremental term facility and a $25.0 million senior secured incremental revolving facility.
- Termination Fees: Approximately $48.6 million is payable under specific termination scenarios (e.g., change of recommendation, superior proposal). This fee reduces to approximately $24.3 million if a superior proposal is entered into during the "Go-Shop" period or shortly thereafter.
Material Changes and Transaction Structure
The filing represents a material change in corporate structure and strategy for both entities. Key structural elements include:
- Merger Mechanics: The transaction involves a "First Merger" of a subsidiary into NV5, followed by a "Second Merger" of the surviving entity into another Acuren subsidiary.
- Equity Awards: Unvested NV5 restricted stock awards (RSAs) will generally be replaced with Acuren RSAs. Certain executive RSAs and non-employee director RSUs will fully vest immediately prior to the closing and convert into merger consideration.
- Governance: Upon closing, the Acuren Board will expand to include three designees from NV5, including NV5 Executive Chairman Dickerson C. Wright. The total board size is anticipated to be eleven members.
- Go-Shop Period: NV5 is permitted to solicit alternative proposals until July 14, 2025. Following this date, standard "no-shop" restrictions apply, subject to a fiduciary out.
Guidance, Outlook, Risks, and Contingencies
The filing contains no specific financial guidance or revenue outlook for the combined entity. Management commentary focuses on the strategic rationale and the approval process.
- Conditions to Closing: The transaction is subject to customary conditions, including stockholder approval from both companies, regulatory clearance (Hart-Scott-Rodino and foreign investment laws), effectiveness of the Form S-4 registration statement, and NYSE listing approval.
- Termination Rights: Either party may terminate if the deal is not consummated by October 3, 2025 (extendable to November 3, 2025 if only regulatory clearance remains). NV5 may also terminate to pursue a superior proposal upon payment of the termination fee.
- Risks: Significant risks include failure to obtain stockholder or regulatory approval, inability to secure financing, disruption of business operations, and failure to realize anticipated synergies.
- Voting Support: Acuren has secured voting support agreements from NV5 stockholders holding approximately 16.7% of NV5 voting power. NV5 has secured voting support from Acuren stockholders holding approximately 44.7% of Acuren voting power.
Important Facts for Investor Verification
- Stockholder Approval: Verify the outcome of the special meetings for both Acuren and NV5 stockholders, as the transaction is contingent upon their approval.
- Regulatory Clearance: Monitor the status of antitrust and foreign investment clearance, which is a condition to closing.
- Financing Confirmation: Confirm that the $875.0 million debt financing is finalized and funded, as NV5's obligation to close is conditioned on Acuren obtaining this financing.
- Go-Shop Outcome: Watch for announcements regarding any superior proposals received during the Go-Shop period ending July 14, 2025.
- Form S-4 Filing: Review the upcoming joint proxy statement/prospectus (Form S-4) for detailed financial projections, risk factors, and the final terms of the merger consideration.